CN104530152A - Compound containing acrylonitrile base and trifluoro methoxyphenyl O-galactoside structure and application - Google Patents

Compound containing acrylonitrile base and trifluoro methoxyphenyl O-galactoside structure and application Download PDF

Info

Publication number
CN104530152A
CN104530152A CN201510021053.6A CN201510021053A CN104530152A CN 104530152 A CN104530152 A CN 104530152A CN 201510021053 A CN201510021053 A CN 201510021053A CN 104530152 A CN104530152 A CN 104530152A
Authority
CN
China
Prior art keywords
compound
acid
application
obtains
vii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510021053.6A
Other languages
Chinese (zh)
Inventor
蔡子洋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Foshan Saiweisi Pharmaceutical Technology Co Ltd
Original Assignee
Foshan Saiweisi Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foshan Saiweisi Pharmaceutical Technology Co Ltd filed Critical Foshan Saiweisi Pharmaceutical Technology Co Ltd
Priority to CN201510021053.6A priority Critical patent/CN104530152A/en
Publication of CN104530152A publication Critical patent/CN104530152A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Abstract

The invention relates to the field of diabetic drugs, in particular to an SGLT2 inhibitor containing an acrylonitrile base and trifluoro methoxyphenyl O-galactoside structure, a preparation method of the SGLT2 inhibitor and the application of the SGLT2 inhibitor in preparing diabetic drugs.

Description

A kind of containing acrylonitrile group and trifluoromethoxy benzaldehyde base O-glucoside structural compounds and purposes
Technical field
The present invention relates to the pharmaceutical field relevant to diabetes B.Specifically, the present invention relates to a kind of to medicative 2 type sodium dependent glucoses transhipment (SGLT2) inhibitor, preparation method and the purposes containing acrylonitrile group and trifluoromethoxy benzaldehyde base O-glucoside structure of diabetes B.
Background technology
Whole world diabetic subject presents the trend increased gradually, and wherein about the overwhelming majority is diabetes B patient.Sulfonylurea, N1,N1-Dimethylbiguanide class, thiazolidinediones, alpha-glucosidase inhibitor class, dipeptidyl peptidase-iv inhibitor class and trypsin class medicine is mainly contained at present at the antidiabetic medicine of Clinical practice.These medicines have good therapeutic action, but long-term treatment exists comparatively severe side effect, and owing to there is resistance, in some cases in time drug combination be all difficult to the blood sugar controlling patient.
2 type sodium dependent glucoses transhipment (SGLT2) are the novel targets of the treatment diabetes of discovered in recent years.SGLT2 is mainly distributed in renal proximal tubules, and its effect absorbs the glucose in urine, and returns it in blood, therefore suppresses that SGLT2's just can reduce the concentration of glucose in blood.When SGLT2 function is suppressed, more glucose will be secreted from urine, this glucose level that will contribute to diabetic subject and keep correct.
Chinese patent CN200610093189.9 discloses the compound of having structure as SGLT2 inhibitor:
Wherein, A is O, S, NH, (CH 2) n, n=0-3.
Chinese patent CN200380110040.1 discloses the compound of having structure as SGLT2 inhibitor:
Wherein, A is covalent linkage, O, S, NH, (CH 2) n, n=1-3.
The invention discloses a kind of containing vinyl cyanide and trifluoromethoxy benzaldehyde base O-glucoside analog derivative as novel SGLT2 inhibitor, these compounds can be used for preparing the medicine for the treatment of diabetes particularly diabetes B.
Summary of the invention
An object of the present invention is the shortcoming and defect overcoming prior art, provide one to have excellent activity, there is the compound of formula I and pharmaceutically can accept prodrug ester.
Another object of the present invention is to provide preparation and has the compound of formula I and the method for pharmaceutically acceptable prodrug ester thereof.Another object is to provide the compound containing formula I and the application in treatment diabetes thereof.Now in conjunction with object of the present invention, content of the present invention is specifically described.
The compound that the present invention has formula I has following structural formula:
Formula I of the present invention is synthesized by following route:
Compound II per CH 3oCH 2group (MOM) is protected, and obtains III; Compound III changes corresponding acyl chlorides IV into; Compound V with after NaH process and IV react, finally use Me 2sO 4be obtained by reacting VI; VI acid treatment obtains VII; VII and VIII is obtained by reacting IX; IX deacetylate obtains I; The described reagent being converted into acyl chlorides comprises SOCl 2, PCl 3, PCl 5(COCl) 2; Described acid is selected from mineral acid and following organic acid, methylsulfonic acid, trifluoromethanesulfonic acid, trifluoroacetic acid, trichoroacetic acid(TCA).
The pharmaceutically acceptable prodrug ester of formula I of the present invention, comprises the ester that any one or more hydroxyl in molecule and ethanoyl, pivaloyl group, various phosphoryl, formamyl, alkoxyl formyl etc. are formed.
Formula I of the present invention has the restraining effect of SGLT2, can be used as the medicine of effective constituent for the preparation of diabetes aspect.The activity of formula I of the present invention is verified by receptor binding assays.Formula I of the present invention is effective in quite wide dosage range.The dosage that such as every day takes, within the scope of 1mg-300mg/ people, is divided into once or administration for several times.The actual dosage taking formula I can be decided according to relevant situation by doctor.These situations comprise: the physical state of patient, route of administration, age, body weight, individual reaction to medicine, the severity etc. of symptom.
Embodiment
Below in conjunction with embodiment, the present invention is further illustrated.It should be noted that, following embodiment be only for illustration of, and not for limiting the present invention.The various changes that those skilled in the art's training centre according to the present invention is made all should within the protection domain required by the application's claim.
The preparation of embodiment 1 Compound I
22.2g (100mmol) Compound II per and 12.08g (150mmol) CH 3oCH 2cl (MOMCl) is dissolved in the DMF of 250mL drying, stirs, adds 55.28g (400mmol) solid K 2cO 3, then at N 2lower stirring is spent the night, and TLC detection reaction completes.Be poured into after reaction mixture is slightly cold in 1000mL frozen water, under stirring, regulate pH=2 with concentrated hydrochloric acid, 200mL × 3 dichloromethane extraction, brine It, anhydrous sodium sulfate drying, evaporate to dryness on Rotary Evaporators, the resistates obtained is III, faint yellow solid, ESI-MS, m/z=265 [M-H] -, for next step reaction.
Above-mentioned III is dissolved in the methylene dichloride of 100mL drying, and ice-water bath cooling is lower stirs, and slowly drips 12.69g (100mmol) SOCl 2, at a low price, drip DMF, then a room temperature for overnight.Reaction mixture is evaporate to dryness on a rotary evaporator, and the resistates obtained is IV, white solid, for next step reaction.
3.30g (50mmol) the third two eyeball (V) is dissolved in the THF of 100mL drying, ice-water bath cooling is lower stirs, slowly add 4.80g (120mmol, 60%) NaH, after adding, more slowly add 10.03g (50mmol) IV and be dissolved in the solution that 10mL THF makes.Dropwise rear continuation stirring 1 hour, then drip 7.57g (60mmol) methyl-sulfate, dropwise rear room temperature for overnight.Reaction mixture is poured in 500mL frozen water, under stirring, regulates pH=5 with concentrated hydrochloric acid, 100mL × 3 dichloromethane extraction, brine It, anhydrous sodium sulfate drying, evaporate to dryness on Rotary Evaporators, the resistates obtained is VI, column chromatography purification, obtains sterling VI, white solid, ESI-MS, m/z=329 [M+H] +.
9.84g (30mmol) compound VI-1 is dissolved in 100mL MeOH, and ice-water bath cooling is lower stirs, and slowly drip 0.5mL concentrated hydrochloric acid, stirred at ambient temperature 3 hours, reaction completes.Reaction mixture is poured in 500mL frozen water, stirs, 100mL × 3 dichloromethane extraction, brine It, anhydrous sodium sulfate drying, evaporate to dryness on Rotary Evaporators, the resistates obtained is VII, column chromatography purification, obtain sterling VII, white solid, ESI-MS, m/z=285 [M+H] +.
5.68g (20mmol) compound VI I and 12.34g (30mmol) compound VI II is dissolved in 50mL methylene dichloride, stir, slowly add the solution be made up of 0.80g (20mmol) NaOH and 10mL water, then add 1g tetra-n-butyl ammonium bromide again.Room temperature for overnight.TLC checks that reaction completes.Reaction mixture is poured in 500mL frozen water, stirs, 100mL × 3 dichloromethane extraction, brine It, anhydrous sodium sulfate drying, evaporate to dryness on Rotary Evaporators, the resistates obtained is IX, column chromatography purification, obtain sterling IX, white solid, ESI-MS, m/z=615 [M+H] +.
6.14g (10mmol) Compound I X is dissolved in the 30mL MeOH containing 0.6g MeONa, then stirred at ambient temperature 3 hours, and reaction completes.Then add the storng-acid cation exchange resin of 5g drying, room temperature for overnight.Suction filtration, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained is positive empty dry, obtains Compound I, white solid, ESI-MS, m/z=447 [M+H] +.
The preparation of embodiment 2 reference compound D-1
In order to further illustrate the drug effect of the compounds of this invention, this invention describes not yet open and being all the Compound D-1 of the applicant's design.
Its preparation method is as follows:
13.8g (100mmol) Compound II per-2 and 12.08g (150mmol) CH 3oCH 2cl (MOMCl) is dissolved in the DMF of 250mL drying, stirs, adds 55.28g (400mmol) solid K 2cO 3, then at N 2lower stirring is spent the night, and TLC detection reaction completes.Be poured into after reaction mixture is slightly cold in 1000mL frozen water, under stirring, pH=2 is regulated, 200mL × 3 dichloromethane extraction, brine It with concentrated hydrochloric acid, anhydrous sodium sulfate drying, evaporate to dryness on Rotary Evaporators, the resistates obtained is III-2, faint yellow solid, ESI-MS, m/z=181 [M-H] -, for next step reaction.
Above-mentioned III-2 is dissolved in the methylene dichloride of 100mL drying, and ice-water bath cooling is lower stirs, and slowly drips 12.69g (100mmol) SOCl 2, at a low price, drip DMF, then a room temperature for overnight.Reaction mixture is evaporate to dryness on a rotary evaporator, and the resistates obtained is IV-2, white solid, for next step reaction.
3.30g (50mmol) the third two eyeball (V) is dissolved in the THF of 100mL drying, ice-water bath cooling is lower stirs, slowly add 4.80g (120mmol, 60%) NaH, after adding, more slowly add 10.03g (50mmol) IV-2 and be dissolved in the solution that 10mL THF makes.Dropwise rear continuation stirring 1 hour, then drip 7.57g (60mmol) methyl-sulfate, dropwise rear room temperature for overnight.Reaction mixture is poured in 500mL frozen water, under stirring, regulates pH=5 with concentrated hydrochloric acid, 100mL × 3 dichloromethane extraction, brine It, anhydrous sodium sulfate drying, evaporate to dryness on Rotary Evaporators, the resistates obtained is VI-2, column chromatography purification, obtains sterling VI-2, white solid, ESI-MS, m/z=245 [M+H] +.
7.32g (30mmol) compound VI-2 is dissolved in 100mL MeOH, and ice-water bath cooling is lower stirs, and slowly drip 0.5mL concentrated hydrochloric acid, stirred at ambient temperature 3 hours, reaction completes.Reaction mixture is poured in 500mL frozen water, stirs, 100mL × 3 dichloromethane extraction, brine It, anhydrous sodium sulfate drying, evaporate to dryness on Rotary Evaporators, the resistates obtained is VII-2, column chromatography purification, obtain sterling VII-2, white solid, ESI-MS, m/z=201 [M+H] +.
4.00g (20mmol) compound VI I-2 and 12.34g (30mmol) compound VI II is dissolved in 50mL methylene dichloride, stir, slowly add the solution be made up of 0.80g (20mmol) NaOH and 10mL water, then add 1g tetra-n-butyl ammonium bromide again.Room temperature for overnight.TLC checks that reaction completes.Reaction mixture is poured in 500mL frozen water, stirs, 100mL × 3 dichloromethane extraction, brine It, anhydrous sodium sulfate drying, evaporate to dryness on Rotary Evaporators, the resistates obtained is IX-2, column chromatography purification, obtain sterling IX-2, white solid, ESI-MS, m/z=531 [M+H] +.
5.30g (10mmol) Compound I X-2 is dissolved in the 30mL MeOH containing 0.6g MeONa, then stirred at ambient temperature 3 hours, and reaction completes.Then add the storng-acid cation exchange resin of 5g drying, room temperature for overnight.Suction filtration, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained is positive empty dry, obtains D-1, white solid, ESI-MS, m/z=363 [M+H] +.
Embodiment 3
The IC that compound of the present invention and related compound suppress SGLT2 50the method that value reference literature is recorded measures (Meng, W.et al, J.Med.Chem., 2008,51,1145-1149).
The carrier using the Chinese hamster ovary celI of stably express humanization SGLT2 to analyze as transhipment, uses the substrate that [14C]-α-D-methyl glucoside ([14C]-AMG) analyzes as transhipment.By stably express, the Chinese hamster ovary celI of humanization SGLT2 is inoculated on 96 orifice plates, and 12 hours are hatched at 37 DEG C, every hole by the KRH-Na+ washing lotion of 200 μ L (containing 120mM NaCl, 4.7mM KCl, 1.2mM MgCl2,2.2mM CaCl2,10mM HEPES and 1mM Tris (pH=7.4)) wash 3 times, then the KRH-Na+ washing lotion containing testing compound or blank is added in every hole, each testing compound arranges 10 concentration, and last each hole adds the washing lotion that 100 μ L contain [14C]-AMG (10 μ Ci/mL).96 orifice plates hatch 1 hour subsequently at 37 DEG C, then every hole adds the ice-cold stop buffer of 100 μ L (containing 120mM NaCl, 4.7mM KCl, 1.2mM MgCl2,2.2mM CaCl2,10mM HEPES, 1mM Tris and 10mM phlorizin (pH=7.4)), 5 times are washed again subsequently, each every hole 100 μ L with this stop buffer.Every Kong Zhongzai adds the ice-cold cytolysate (100mM NaOH) of 20 μ L, then shakes 5 minutes with the speed of 600rpm, and then Microscint 40 liquid adding 80 μ L in every hole dodges liquid, then shakes 5 minutes with the speed of 600rpm.Finally, this 96 orifice plate is at the upper counting of MicroBeta Trilux liquid scintillation counter (PerkinElmer).Response curve use experience four parameter model measures 503nhibiting concentration, is expressed as IC50.Shown in the following list of result.
Part of compounds of the present invention is to the IC of SGLT2 50value
Compound IC 50(hSGLT2,nM)
Compound I 15.3
Reference compound D-1 26.1
Above-mentioned IC 50measurement result show, compound of the present invention is strong SGLT2 inhibitor, can be used for prepare treatment diabetes B medicine.

Claims (3)

1. there is compound and the pharmaceutically acceptable prodrug ester thereof of formula I structure,
2. synthesize the method for compound described in claim 1:
Compound II per CH 3oCH 2radical protection, obtains III; Compound III changes corresponding acyl chlorides IV into; Compound V with after NaH process and IV react, finally use Me 2sO 4be obtained by reacting VI; VI acid treatment obtains VII; VII and VIII is obtained by reacting IX; IX deacetylate obtains I; The described reagent being converted into acyl chlorides is selected from SOCl 2, PCl 3, PCl 5(COCl) 2; Described acid is selected from methylsulfonic acid, trifluoromethanesulfonic acid, trifluoroacetic acid, trichoroacetic acid(TCA).
3. compound described in claim 1 and pharmaceutically acceptable salt and the application of prodrug ester in preparation treatment diabetes medicament.
CN201510021053.6A 2015-01-15 2015-01-15 Compound containing acrylonitrile base and trifluoro methoxyphenyl O-galactoside structure and application Pending CN104530152A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510021053.6A CN104530152A (en) 2015-01-15 2015-01-15 Compound containing acrylonitrile base and trifluoro methoxyphenyl O-galactoside structure and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510021053.6A CN104530152A (en) 2015-01-15 2015-01-15 Compound containing acrylonitrile base and trifluoro methoxyphenyl O-galactoside structure and application

Publications (1)

Publication Number Publication Date
CN104530152A true CN104530152A (en) 2015-04-22

Family

ID=52845817

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510021053.6A Pending CN104530152A (en) 2015-01-15 2015-01-15 Compound containing acrylonitrile base and trifluoro methoxyphenyl O-galactoside structure and application

Country Status (1)

Country Link
CN (1) CN104530152A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114315586A (en) * 2021-12-23 2022-04-12 江苏浩丰生物科技有限公司 Vanillic acid farnesyl ester, preparation method thereof and application thereof in tobacco industry
CN114315587A (en) * 2021-12-23 2022-04-12 江苏浩丰生物科技有限公司 Vanillic acid linalyl ester, preparation method thereof and application thereof in tobacco industry

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101445527A (en) * 2008-12-25 2009-06-03 天津药物研究院 Five-membered heteroaromatics tolylene glucoside and preparation method and use thereof
WO2014152518A2 (en) * 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101445527A (en) * 2008-12-25 2009-06-03 天津药物研究院 Five-membered heteroaromatics tolylene glucoside and preparation method and use thereof
WO2014152518A2 (en) * 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ADITYA KULKARNI ET AL.: "1,3-Disubstituted-4-Aminopyrazolo [3, 4-d] Pyrimidines, a New Class of Potent Inhibitors for Phospholipase D", 《CHEMICAL BIOLOGY & DRUG DESIGN》 *
RINA HEROWATI ET AL.: "Molecular Docking Studies of Chemical ConstituentsofTinospora cordifoliaon Glycogen Phosphorylase", 《PROCEDIA CHEMISTRY》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114315586A (en) * 2021-12-23 2022-04-12 江苏浩丰生物科技有限公司 Vanillic acid farnesyl ester, preparation method thereof and application thereof in tobacco industry
CN114315587A (en) * 2021-12-23 2022-04-12 江苏浩丰生物科技有限公司 Vanillic acid linalyl ester, preparation method thereof and application thereof in tobacco industry
CN114315586B (en) * 2021-12-23 2023-12-08 江苏浩丰生物科技有限公司 Acacia vanillate and preparation method and application thereof in tobacco industry
CN114315587B (en) * 2021-12-23 2023-12-08 江苏浩丰生物科技有限公司 Linalyl vanillate, preparation method thereof and application thereof in tobacco industry

Similar Documents

Publication Publication Date Title
CN104530152A (en) Compound containing acrylonitrile base and trifluoro methoxyphenyl O-galactoside structure and application
CN104497072A (en) Derivative containing acrylonitrile and benzene halide O-glucoside structures and preparation method and application thereof
CN104497071A (en) Compound with acrylonitrile group and cyanobenzene-O-glucoside structure and application
CN104497074A (en) Compound with acrylonitrile group and nitrobenzene-O-glucoside structure and application
CN104478960A (en) Compound containing acrylonitrile-based and benzotrifluoride-based O-glucoside structure and application
CN104497073A (en) Derivative containing acrylonitrile and benzene halide O-glucoside structures and preparation method and application thereof
CN104478964A (en) Benzene O-glucoside derivative with acrylonitrile structure and preparation method and application thereof
CN104478961A (en) Benzene O-glucoside structure derivative with acrylonitrile and amino group and preparation method and application thereof
CN105237595A (en) N2-glycosyl-substituted 1,2,3-triazole compound and synthesis method and application thereof
CN104530149A (en) Halogen-substituted phenyl group double-O-glucoside derivant, and preparation method and application thereof
CN104478963A (en) Compound containing nitrile-based benzene S-glucoside structure and application of compound
CN104497070A (en) Compound with trifluoromethyl-S-glucoside and application
CN104530151A (en) Compound containing nitrobenzene S-glucoside structure and application thereof
CN104497068A (en) Compound with trifluoromethoxybenzene-S-glucoside structure and application thereof
CN104447906A (en) Alcoxyl phenyl group diosgenin-diglucoside derivative and preparation method and application thereof
CN104447905A (en) Derivative containing nitrobenzene and bis-O-glucoside and preparation method and application of derivative
CN104497069A (en) Amido phenyl S-glucoside derivative, preparation method and use thereof
CN104478959A (en) Compound with nitrile group biphenyl double-glucoside structure and preparation method and application thereof
CN104530150A (en) Compound with amino benzene and diosgenin-diglucoside structure and preparation method and application thereof
CN104478675B (en) One class contains derivative and the purposes of alkoxyphenyl radical and fluoroform phenyl propylene glycol structure
CN104447907A (en) Compound containing nitro biphenyl diosgenin-diglucoside structure and preparation method and application thereof
CN104478956A (en) Phenyl double O-glucoside derivative and preparation method and application thereof
CN104529720B (en) One class is containing derivative, the Preparation Method And The Use of trifluoromethoxy benzaldehyde base propylene glycol structure
CN104478957A (en) Derivative containing nitrile-based benzene and bis-O-glucoside, preparation method thereof and application
CN104530158A (en) O-galactoside derivative containing 2-naphthyl benzene thiazolyl, preparation method and application

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150422